Digi.Bio brings biotechnology to the 21st century by leveraging Digital Microfluidics, integrated sensors and AI. Despite the ever growing demand in the field of Synthetic Biology, laboratory researchers are still largely performing manual pipetting between bulky machines to perform their experiments.

The platform that Digi.Bio developed performs automated laboratory experiments, miniaturized, and integrated with a cloud dashboard to control operations, record data and use AI technology to optimize experimentation. The amount of reagent used is reduced up to 100x while hands-on time for the researcher is reduced by 80%. But most importantly: performing experiments becomes as easy as using your computer.

Part of this platform is a benchtop device called the Biological Processing Unit: BPU; it holds a disposable microfluidic cartridge to manipulate the reagents for an experiment. It contains temperature control and purification system to influence experimental conditions, and optical sensors to collect sample data. On the other hand is a cloud dashboard where experiments can be selected, configured and started, and data is collected from the sensors. Machine learning and AI can take this data and help create models for complex biological systems, or automatically plan series of experiments for a research plan.

The business model of Digi.Bio is founded on one time sales of BPU’s, with recurrent revenue from customers for buying microfluidic cartridges. Customers will get free access to the cloud platform. Currently, the Beta program is being rolled out and shipment to first Beta customers will start soon.

Digi.Bio was founded in February 2017 by three enthusiastic young entrepreneurs that saw the potential of Digital Microfluidics: a new approach to liquid handling for Synthetic Biology Research. With a diverse background across Metabolic Engineering, BioInformatics, Synthetic Biology, Artificial Intelligence, Software development and Hardware development, this team is confident to make this vision reality. more